DIAGNOS Appoints New Chief Operating Officer

written by Raj Shah | January 16, 2024

January 16, 2024 (Source) – Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, is pleased to announce the appointment of Mr. Yves-Stéphane Couture as Chief Operating Officer. As part of his duties, Mr. Couture will be responsible for the continuous development of our flagship product CARA as well as its commercialization worldwide.

Mr. Couture joined DIAGNOS in 2017. Since then, he has been a key asset in the development of AI-based solutions used by optometrists and ophthalmologists to detect and classify multiple illnesses through the analysis of fundus pictures as well as retina scans. Yves-Stéphane strongly believes that AI-based solutions is key to solving some of the most important challenges facing healthcare providers in the delivery of care to patients. "By his actions, Yves-Stéphane has shown total dedication to the success of the Corporation and, on behalf of our employees and directors, I wish him the best in his continued efforts to grow our revenues," said Mr. André Larente, President of DIAGNOS. Mr. Couture's new role is effective January 15, 2024.

Prior to joining DIAGNOS, Mr. Couture led sales and implementation teams with large IT and telecommunication companies, such as Alcatel-Lucent and Teleglobe, where he was in charge of commercializing and implementing complex infrastructure solutions for health care providers and hospitals. Mr. Couture holds a Bachelor degree in administration

from the University of Sherbrooke where he also received a master degree in marketing.

The board of directors of the Corporation has approved a grant of 100,000 stock options to Mr. Couture. The date of the grant is January 15, 2024. Stock options vest at 50% per year, commencing with the first anniversary of the grant. The exercise price of the stock options has been established at $0.41 per common share. The expiry date to which the stock options can be exercised has been fixed to January 15, 2029.

All monies quoted in this press release shall be stated and paid in lawful money of Canada.

About DIAGNOS

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

Additional information is available at www.diagnos.ca and http://www.sedar.com.

This press release contains forward-looking information. We cannot guarantee that the forward-looking information mentioned will prove to be accurate, as there may be a significant discrepancy between actual results or future events and those mentioned in this statement. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this press release is expressly covered by this caution.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.